Global Data01.27.20
Medical technology manufacturer Raumedic has launched the Raumed Home ICP, a new home-use device for intracranial pressure (ICP) monitoring. Having recently received CE marking, the device is well positioned to access the ICP monitoring devices market, which is estimated to reach $181.9 million by 2025, growing at a compound annual growth rate (CAGR) of 2.4 percent, according to Global Data.
The launch of the Raumed Home ICP is expected to disrupt the market, giving neurosurgeons better insights for therapy and allowing hydrocephalus patients to lead a more active life, claimed GlobalData, a data and analytics company.
The product was developed for patients suffering from hydrocephalus, a condition in which excessive amounts of cerebrospinal fluid (CSF) is accumulated in the brain.
Aliyah Farouk, medical device analyst at GlobalData, explained: “For neuro-monitoring, a telemetric catheter is implanted in the patient’s cranium in a 20-minute procedure, allowing ICP to be directly measured from the brain’s tissue. A circular reader antenna is then placed above the catheter to register and store the ICP data. During the measurement, the patient is able to freely move in their home environment and select or store certain activities or events on the handheld device, such as headaches, sleeping, eating, and nausea, with the touch of a button.”
There are numerous ICP monitoring devices currently on the market. ICP monitoring using an external ventricular drainage (EVD) device is considered the gold standard. This technique involves the surgical insertion of a catheter into the ventricles of the brain, which allows ICP measurement and CSF drainage.
However, this method is not ideal for patients with small ventricles or patients with brain swelling. Additionally, the long-term usage of EVDs can increase the risk of intracranial infection. ICP monitoring directly from the tissue of the brain is considered more accurate and with lower incidence of infection and bleeding.
The launch of the Raumed Home ICP is expected to disrupt the market, giving neurosurgeons better insights for therapy and allowing hydrocephalus patients to lead a more active life, claimed GlobalData, a data and analytics company.
The product was developed for patients suffering from hydrocephalus, a condition in which excessive amounts of cerebrospinal fluid (CSF) is accumulated in the brain.
Aliyah Farouk, medical device analyst at GlobalData, explained: “For neuro-monitoring, a telemetric catheter is implanted in the patient’s cranium in a 20-minute procedure, allowing ICP to be directly measured from the brain’s tissue. A circular reader antenna is then placed above the catheter to register and store the ICP data. During the measurement, the patient is able to freely move in their home environment and select or store certain activities or events on the handheld device, such as headaches, sleeping, eating, and nausea, with the touch of a button.”
There are numerous ICP monitoring devices currently on the market. ICP monitoring using an external ventricular drainage (EVD) device is considered the gold standard. This technique involves the surgical insertion of a catheter into the ventricles of the brain, which allows ICP measurement and CSF drainage.
However, this method is not ideal for patients with small ventricles or patients with brain swelling. Additionally, the long-term usage of EVDs can increase the risk of intracranial infection. ICP monitoring directly from the tissue of the brain is considered more accurate and with lower incidence of infection and bleeding.